Last reviewed · How we verify

Haemophilus Influenzae Acute Otitis Media — Treatment Landscape & Competitive Intelligence

Haemophilus Influenzae Acute Otitis Media (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Influenzae Acute Otitis Media, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Cedax ceftibuten Burke Therap Cephalosporin Antibacterial 1995-01-01
Zithromax azithromycin Pfizer Inc. Macrolide antibiotic (azalide) Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor 1991-11-01
Biaxin clarithromycin Generic (originally Abbott/AbbVie) Macrolide Antimicrobial [EPC] Potassium voltage-gated channel subfamily H member 2 1991-10-31
Cefzil cefprozil Teva Pharmaceuticals USA Cephalosporin Antibacterial [EPC] 1991-01-01
Ceftin CEFUROXIME AXETIL GSK Cephalosporin Antibacterial 1987-01-01
Augmentin 250 CLAVULANIC ACID Dr Reddys Labs Inc beta Lactamase Inhibitor 1984-01-01
Zinacef CEFUROXIME GSK Cephalosporin Antibacterial Carbonic anhydrase 2 1983-01-01
Cefradex cefradine Bristol-Myers Squibb cefradine Matrix metalloproteinase-9 1974-01-01
Trimethoprim TRIMETHOPRIM Dr Reddys Labs Sa Sulfonamide Antimicrobial [EPC] Dihydrofolate reductase 1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Haemophilus Influenzae Acute Otitis Media
  2. · 3 drugs in Haemophilus Influenzae Acute Otitis Media
  3. GSK · 2 drugs in Haemophilus Influenzae Acute Otitis Media
  4. Bristol-Myers Squibb · 2 drugs in Haemophilus Influenzae Acute Otitis Media
  5. Dr Reddys Labs Sa · 1 drug in Haemophilus Influenzae Acute Otitis Media
  6. Generic (originally Abbott/AbbVie) · 1 drug in Haemophilus Influenzae Acute Otitis Media
  7. Generic (originally Abbott/Lilly) · 1 drug in Haemophilus Influenzae Acute Otitis Media
  8. Generic (originally Beecham/GSK) · 1 drug in Haemophilus Influenzae Acute Otitis Media
  9. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Haemophilus Influenzae Acute Otitis Media
  10. Johnson And Johnson · 1 drug in Haemophilus Influenzae Acute Otitis Media
  11. King George's Medical University · 1 drug in Haemophilus Influenzae Acute Otitis Media
  12. Pfizer Inc. · 1 drug in Haemophilus Influenzae Acute Otitis Media

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Influenzae Acute Otitis Media:

Cite this brief

Drug Landscape (2026). Haemophilus Influenzae Acute Otitis Media — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-influenzae-acute-otitis-media. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing